ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Pepperstone

Trade Now

Pepperstone
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
S&P ASX 200
7,569.90
-1.23%
S&P ASX All Technology
2,968.80
-1.53%
Brent Oil
85.515
-0.44%
US Dollar vs AUD
1.54118
-0.19%
Bitcoin
57,285.33
-5.47%
Registration Strip Icon for pro Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. Esperion Therapeutics Inc (ESPR)

  7. Esperion Therapeutics Inc (ESPR) News

ESPR

Esperion Therapeutics (ESPR)

Esperion Therapeutics Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:ESPR
DateTimeSourceHeadlineSymbolCompany
29/04/202422:00GlobeNewswire Inc.Esperion to Participate in Upcoming May Investor ConferencesNASDAQ:ESPREsperion Therapeutics Inc
23/04/202422:00GlobeNewswire Inc.Esperion to Report First Quarter 2024 Financial Results on May 7NASDAQ:ESPREsperion Therapeutics Inc
08/04/202404:45GlobeNewswire Inc.Esperion Presents Important New Data from CLEAR Outcomes at ACC.24 Highlighting Value of NEXLETOL® (bempedoic acid) Tablets in Diverse Populations Including Women, Hispanics/Latinx and Patients with ObesityNASDAQ:ESPREsperion Therapeutics Inc
01/04/202423:00GlobeNewswire Inc.Esperion to Ring Nasdaq Opening Bell Today, April 1, 2024NASDAQ:ESPREsperion Therapeutics Inc
26/03/202423:00GlobeNewswire Inc.Esperion to Participate in 23rd Annual Needham Virtual Healthcare ConferenceNASDAQ:ESPREsperion Therapeutics Inc
26/03/202407:00GlobeNewswire Inc.Esperion Announces Data from CLEAR Outcomes Sub-Groups as Poster Presentations, Moderated Session & Industry Expert Theatre to be Presented at ACC.24NASDAQ:ESPREsperion Therapeutics Inc
23/03/202409:26Business WireU.S. FDA Approves Broad New Labels for Esperion’s NEXLETOL® and NEXLIZET® to Prevent Heart Attacks and Cardiovascular Procedures in Both Primary and Secondary Prevention Patients, Regardless of Statin UseNASDAQ:ESPREsperion Therapeutics Inc
23/03/202406:10GlobeNewswire Inc.U.S. FDA Approves Broad New Labels for NEXLETOL® and NEXLIZET® to Prevent Heart Attacks and Cardiovascular Procedures in Both Primary and Secondary Prevention Patients, Regardless of Statin UseNASDAQ:ESPREsperion Therapeutics Inc
23/03/202402:04GlobeNewswire Inc.CHMP Issues Positive Opinions For Both Bempedoic Acid And The Bempedoic Acid / Ezetimibe Fixed-Dose Combination Tablet As Treatments For Hypercholesterolemia And Significantly Reducing Cardiovascular EventsNASDAQ:ESPREsperion Therapeutics Inc
28/02/202401:19Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:ESPREsperion Therapeutics Inc
27/02/202423:23Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ESPREsperion Therapeutics Inc
27/02/202422:00GlobeNewswire Inc.Esperion Reports Fourth Quarter and Full Year 2023 Financial ResultsNASDAQ:ESPREsperion Therapeutics Inc
17/02/202408:30GlobeNewswire Inc.Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)NASDAQ:ESPREsperion Therapeutics Inc
15/02/202406:14Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:ESPREsperion Therapeutics Inc
15/02/202402:50Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:ESPREsperion Therapeutics Inc
15/02/202400:42Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:ESPREsperion Therapeutics Inc
14/02/202422:11Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:ESPREsperion Therapeutics Inc
14/02/202400:00GlobeNewswire Inc.Esperion to Report Fourth Quarter and Full Year 2023 Financial Results on February 27NASDAQ:ESPREsperion Therapeutics Inc
02/02/202406:00GlobeNewswire Inc.RFK, Esperion Therapeutics Announce 2024 Promotional ScheduleNASDAQ:ESPREsperion Therapeutics Inc
24/01/202408:00GlobeNewswire Inc.Esperion Announces Closing of Public Offering of Common Stock and Exercise in Full of Underwriters’ Option to Purchase Additional SharesNASDAQ:ESPREsperion Therapeutics Inc
22/01/202422:10Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ESPREsperion Therapeutics Inc
22/01/202422:04Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:ESPREsperion Therapeutics Inc
19/01/202413:15GlobeNewswire Inc.Esperion Announces Pricing of $85.1 Million Public Offering of Common StockNASDAQ:ESPREsperion Therapeutics Inc
19/01/202408:03Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ESPREsperion Therapeutics Inc
19/01/202408:01Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:ESPREsperion Therapeutics Inc
19/01/202408:00GlobeNewswire Inc.Esperion Announces Proposed Public Offering of Common StockNASDAQ:ESPREsperion Therapeutics Inc
12/01/202408:09Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ESPREsperion Therapeutics Inc
04/01/202407:15Business WireEsperion e Daiichi Sankyo Europe annunciano un emendamento da 125 milioni di dollari alla loro collaborazione, compresa la risoluzione di una controversia in corsoNASDAQ:ESPREsperion Therapeutics Inc
04/01/202405:54Business WireEsperion et Daiichi Sankyo Europe annoncent une révision de leur collaboration pour un montant s’élevant à 125 millions USD, assortie de la résolution d’un litige en coursNASDAQ:ESPREsperion Therapeutics Inc
04/01/202402:07Business WireEsperion und Daiichi Sankyo Europe geben Anpassung ihrer Zusammenarbeit in Höhe von 125 Millionen US-Dollar sowie die Beilegung eines anhängigen Rechtsstreits bekanntNASDAQ:ESPREsperion Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:ESPR

Your Recent History

SPI
SP500
S&P 500
ASX
XJO
S&P ASX 200
ASX
ANZ
Australia And New Zealan...
ASX
TLS
Telstra
NYSE
MCD
McDonalds
ASX
CBA
Commonwealth Bank Of Aus...
CCOM
SILVER
SILVER
FX
GBPAUD
Sterling vs AUD
ASX
CSL
CSL
NYSE
KO
Coca Cola
NYSE
VZ
Verizon Communications
ASX
XFL
S&P ASX 50
ASX
XMM
S&P ASX 300 Metals and M...
FX
EURAUD
Euro vs AUD
NASDAQ
GOOGL
Alphabet
Delayed Upgrade Clock
ADVFN Logo

Australia
Company
Business
Popular
Get The App

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved